Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMMX with free AI briefings, catalyst countdowns, and dilution alerts.

IMMX · Immix Biopharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $7.48, 29% below $10.54, its close on the day of its Sep 29 underwritten offering. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$336.3M Cash on Hand
83.9mo Cash Runway
Follow IMMX by email Get an email when IMMX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMMX, unsubscribe in one click. Privacy

📣 What IMMX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Dara-CyBorD Light Chain (AL) Amyloidosis Phase 3 · NCT07709715 Not yet recruiting
Evarucabgene Autoleucel (NXC-201) Light Chain (AL) Amyloidosis Phase 3 · NCT07709715 Not yet recruiting
Curcumin/Doxorubicin-encapsulating Nanoparticle… Solid Tumor, Adult Phase 1/2 · NCT03382340 Unknown

Also used in these trials (approved or third-party drugs, not IMMX's own candidates): Tislelizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMMX holds $336.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $12M/quarter from operations, an estimated runway of 83.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMMX files for a raise →

👥 Who Owns IMMX

Insiders 9.4% Institutions (166 holders) 74.6% Public and other holders 16%
HolderTypeShares% of sharesAs of
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 9,783,192 11.67% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 4,539,819 5.42% 2026-09-30
Eventide Asset Management, LLC Institution (13G, 5%+) 3,891,019 4.64% 2026-06-30
Saturn V Capital Management LP Institution (13G, 5%+) 3,693,585 4.41% 2025-12-26
Yekaterina Chudnovsky
Director · +78,500 options
Insider 3,247,326 3.87% 2026-05-22
Ilya M Rachman
CEO and Chairman, Director · +1.18M options
Insider 1,141,683 1.36% 2025-12-10
Carey Ng
Director · +78,500 options
Insider 1,051,471 1.25% 2026-05-22
Jason Hsu
Director · +78,500 options
Insider 949,250 1.13% 2026-05-22
Nancy T Chang
Director · +52,143 options
Insider 925,130 1.10% 2026-05-22
Gabriel S Morris
CFO, President, Director · +1.18M options
Insider 315,570 0.38% 2025-12-08
Helen C. Adams
Director · +78,500 options
Insider 181,004 0.22% 2026-05-22
Magda Marquet
Director · +78,500 options
Insider 72,342 0.09% 2026-05-22

Share count 83,812,456 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMMX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMMX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.